GlassScriptPhysician profile
Harold J Milstein
NPI 1083684344
$119,713.96
in general payments reported to CMS, 2019-2025
46 companies · $3,846 in 2025
The $3,846 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $10K · 2021: $18K · 2022: $28K · 2023: $2,627 · 2024: $4,258 · 2025: $3,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,650 · Food and Beverage: $3,646 · Honoraria: $2,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $675 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,650.00 |
| Food and Beverage | $3,646.40 |
| Honoraria | $2,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $675.00 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,239.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $24,218.85 | 2019-2025 | |
| Genzyme Corporation | $4,451.52 | 2019-2023 | |
| Pfizer INC. | $4,129.43 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,628.80 | 2021 | |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Epi Health, LLC | $2,459.09 | 2019-2022 | |
| Leo Pharma INC. | $2,152.28 | 2019-2023 | Adbry |
| Janssen Biotech, INC. | $1,232.22 | 2019-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,027.72 | 2019-2025 | Siliq, Cabtreo |
| Sun Pharmaceutical Industries INC. | $995.69 | 2019-2024 | Blu-U, Ilumya, Odomzo |
| Galderma Laboratories, L.P. | $749.16 | 2019-2025 | Nemluvio |
| Journey Medical Corporation | $683.52 | 2019-2023 | |
| Lilly USA, LLC | $665.43 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Ucb, INC. | $645.68 | 2019-2025 | Bimzelx, Cimzia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Milstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.